Trial · NCT05067127
Participant flow24
How many started, completed or left each group, period by period.
1 to 20 of 24
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Randomized Controlled Period (26 weeks) | STARTED | Randomized Controlled Period: Pegcetacoplan | 63 | |
| Randomized Controlled Period (26 weeks) | STARTED | Randomized Controlled Period: Placebo | 61 | |
| Randomized Controlled Period (26 weeks) | STARTED | Open-Label Period: Pegcetacoplan to Pegcetacoplan | 0 | |
| Randomized Controlled Period (26 weeks) | STARTED | Open-Label Period: Placebo to Pegcetacoplan | 0 | |
| Randomized Controlled Period (26 weeks) | COMPLETED | Randomized Controlled Period: Pegcetacoplan | 61 | |
| Randomized Controlled Period (26 weeks) | COMPLETED | Randomized Controlled Period: Placebo | 57 | |
| Randomized Controlled Period (26 weeks) | COMPLETED | Open-Label Period: Pegcetacoplan to Pegcetacoplan | 0 | |
| Randomized Controlled Period (26 weeks) | COMPLETED | Open-Label Period: Placebo to Pegcetacoplan | 0 | |
| Randomized Controlled Period (26 weeks) | NOT COMPLETED | Randomized Controlled Period: Pegcetacoplan | 2 | |
| Randomized Controlled Period (26 weeks) | NOT COMPLETED | Randomized Controlled Period: Placebo | 4 | |
| Randomized Controlled Period (26 weeks) | NOT COMPLETED | Open-Label Period: Pegcetacoplan to Pegcetacoplan | 0 | |
| Randomized Controlled Period (26 weeks) | NOT COMPLETED | Open-Label Period: Placebo to Pegcetacoplan | 0 | |
| Open-Label Period (26 weeks) | STARTED | Randomized Controlled Period: Pegcetacoplan | 0 | |
| Open-Label Period (26 weeks) | STARTED | Randomized Controlled Period: Placebo | 0 | |
| Open-Label Period (26 weeks) | STARTED | Open-Label Period: Pegcetacoplan to Pegcetacoplan | 61 | |
| Open-Label Period (26 weeks) | STARTED | Open-Label Period: Placebo to Pegcetacoplan | 57 | |
| Open-Label Period (26 weeks) | COMPLETED | Randomized Controlled Period: Pegcetacoplan | 0 | |
| Open-Label Period (26 weeks) | COMPLETED | Randomized Controlled Period: Placebo | 0 | |
| Open-Label Period (26 weeks) | COMPLETED | Open-Label Period: Pegcetacoplan to Pegcetacoplan | 59 | |
| Open-Label Period (26 weeks) | COMPLETED | Open-Label Period: Placebo to Pegcetacoplan | 55 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05067127/flow